Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV2D5M)

• Drug Name: PMID29649907-Compound-8 Drug Info
• Cross-matching ID: TTD Drug ID: DMV2D5M

Molecule-Related Drug Atlas

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[2]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[3]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[4]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[5]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[6]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[7]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[8]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[9]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[10]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[11]

Drug(s) Targeting G-protein coupled bile acid receptor 1 (GPBAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium taurocholate	DM3GO0J	Type-2 diabetes	5A11	Phase 1/2	[12]
Bile acid	DM9UZD7	Discovery agent	N.A.	Phase 1	[13]
PMID29649907-Compound-INT767	DMA0RI8	N. A.	N. A.	Patented	[1]
INT-767	DMRJ9P4	Hepatic fibrosis	DB93.0	Preclinical	[14]
XL475	DMD8TNK	Type-2 diabetes	5A11	Preclinical	[15]
INT-777	DMTPB8A	Metabolic disorder	5C50-5D2Z	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[1]
G-protein coupled bile acid receptor 1 (GPBAR1)	TTSDVTR	GPBAR_HUMAN	Agonist	[1]

References

• [1] Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364.
• [2] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [3] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [6] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [7] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [8] Clinical pipeline report, company report or official report of ENYO Pharma.
• [9] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [10] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [11] Clinical pipeline report, company report or official report of Metacrine.
• [12] Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
• [13] Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21.
• [14] FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137.
• [15] Clinical pipeline report, company report or official report of Exelixis (2011).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37).